Lettera aperta

Articolo pubblicato su L’altra medicina magazine n 128

Lettera aperta di Alberto Donzelli

1 Chemaitelly H, Ayoub HH, Tang P, et al. Long-term COVID-19 booster effectiveness by infection history and clinical vulnerability and immune imprinting: a retrospective population-based cohort study. Lancet Infect Dis 2023;


2 Tamandjou C, Auvigne V, Schaeffer J, et al. Effectiveness of second booster compared to first booster and protection conferred by previous SARS-CoV-2 infection against symptomatic Omicron BA.2 and BA.4/5 in France. Vaccine 2023;41(17):2754-2760. doi: 10.1016/j.vaccine.2023.03.031.

3 Shrestha NK, Burke PC, Nowacki AS, et al. Effectiveness of the Coronavirus Disease 2019 (COVID-19) Bivalent Vaccine, Open Forum Infectious Diseases, 2023;ofad209, https://doi.org/10.1093/ofid/ofad209.

4 WHO, Global Covid-19 Vaccination Strategy in a Changing World, July 2022 update.

5 Fraiman J, Erviti J, Jones M, et al. Serious adverse events of special interest following mRNA COVID-19 vaccination in randomized trials in adults, Vaccine, 2022, 40: 5798-5805, https://doi.org/10.1016/j.vaccine.2022.08.036.

6 Trougakos IP, Terpos E, Alexopoulos H, et al. Adverse effects of COVID-19 mRNA vaccines: the spike hypothesis. Trends Mol Med. 2022 Jul;28(7):542-554. https://doi.org/10.1016/j.molmed.2022.04.007 Epub 2022 Apr 21.

7 Cosentino M, Marino F. Understanding the pharmacology of COVID-19 mRNA vaccines: playing dice with the spike? Int J Mol Sci 2022; 23(18),10881; https://doi.org/10.3390/ijms231810881

8 Rosenblum HG, Gee J, Liu R, et al. Safety of mRNA vaccines administered during the initial 6 months of the US COVID-19 vaccination programme: an observational study of reports to the Vaccine Adverse Event Reporting System and v-safe.

Lancet Infect Dis 2022;22(6):802-812. http://dx.doi.org/10.1016/S1473-3099(22)00054-8

9 Hause AM, Baggs J, Marquez P, et al. Safety Monitoring of COVID-19 Vaccine Booster Doses Among Adults — United States, September 22, 2021–February 6, 2022. MMWR 2022;71:249-254. 10 Hause AM, Gee J, Baggs J, et al. COVID-19 Vaccine Safety in Adolescents Aged 12–17 Years — United States, December 14, 2020–July 16, 2021. MMWR 2021;70(31):1053-1058. (see Table 3). 11 Mansanguan S, Charunwatthana P, Piyaphanee W, et al. Cardiovascular Manifestation of the BNT162b2 mRNA COVID- 19 Vaccine in Adolescents. Trop Med Infect Dis 2022;7(8):196. http://dx.doi.org/10.3390/tropicalmed7080196

12 Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med 2021; 384:403-416. DOI: 10.1056/NEJMoa2035389. Supplementary Appendix Table S4.

13 Supplement to: Ali K, Berman G, Zhou H, et al. Evaluation of mRNA-1273 SARS-CoV-2 vaccine in adolescents. N Engl J Med. http://dx.doi.org/10.1056/NEJMoa2109522

14 European Centre for Disease Prevention and Control. Interim analysis of COVID-19 vaccine effectiveness against Severe Acute Respiratory Infection due to SARS-CoV-2 in individuals aged 20 years and older – third update. ECDC: Stockholm; 2022. https://www.ecdc.europa.eu/en/publications-data/interim-analysis-covid-19-vaccine-effectiveness-against-severe-acute-respiratory